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Systemic lupus erythematosus (SLE) is a multisystem, 
inflammatory, autoimmune disease characterised by 
the formation of antinuclear antibodies.[1] It is one 
of the most common autoimmune diseases, with 
an estimated incidence of 2.0 - 7.6 per 100 000.[2,3] 
Because SLE can present in a multitude of ways that mimic other 
diseases, early diagnosis can be difficult.
Methods
• A literature review from the first author’s MMed dissertation was 
used as the main reference source. 
• PubMed and Google scholar searches were conducted to identify 
more recent publications. Abstracts from 2014 and 2015 were 
reviewed and relevant full-text articles were read and cross-
referenced.
• Keywords were the following: Systemic Lupus Erythematosus; SLE; 
Children; Update; Management; and Autoantibodies. 
• Personal reference lists of the 3 authors were used in this update.
• Most of the data were either level B or level C.
Who presents with the disease?
Although more commonly present in adults, childhood-onset SLE 
(cSLE) is becoming increasingly recognised, with approximately 
15 - 20% of SLE occurring before the age of 19 years.[1,4] The 
presentation of SLE differs, not only with regard to age, but also 
depending on the ethnic background and gender of the patient.[2,5] 
The disease has been reported to be more common in Europe, Asia 
and the USA than in Africa; yet, patients of African ancestry living 
in these regions have the highest rates of SLE.[6] There is increasing 
recognition that SLE is not as rare in Africa as previously thought. 
The discrepancy may be related to many factors, including under-
diagnosis due to poor access to healthcare and under-recognition 
of the disease.[7]
More females than males are affected with SLE at all ages, but the 
male to female ratio varies. The highest incidence is among women 
of childbearing age, with the female to male ratio from puberty 
to menopause being about 9:1. However, in prepubertal and post-
menopausal patients, this ratio is about 4:1.[2,4]
What causes lupus?
The aetiology of SLE is not fully understood. Genetic, environmental, 
immunological and infective factors are all thought to play a role.[1] It 
is hypothesised that a trigger acts on genetically susceptible indivi-
duals, and complex immune dysregulation of multiple components 
of the immune system as well as disordered apoptosis result in the 
production of autoantibodies that are particularly active against 
proteins in the cell nucleus. Recent evidence is emerging to illustrate 
the intertwined roles of the adaptive and innate immune system 
in this disease, and type 1 interferon has been shown to play a 
prominent role in the development of SLE.[8]
What diagnostic criteria exist?
SLE is diagnosed clinically and in the laboratory. It is based on the 
American College of Rheumatology (ACR) Classification Criteria for 
SLE, which were revised in 1997.[9] Four of the 11 criteria are required 
to make the diagnosis. These criteria were established mainly for use 
in scientific research; therefore many children, especially those with 
lupus nephritis (LN) or antiphospholipid syndrome, might have SLE 
without fulfilling four of the criteria. 
The Systemic Lupus International Collaborating Clinics (SLICC) 
Classification Criteria for SLE have recently been proposed and 
validated in adults with lupus, and have been shown to have greater 
sensitivity but lower specificity compared with the ACR criteria. It 
requires four criteria with at least one clinical and one immunological 
criterion to be present to make the diagnosis.[10]
How do children with lupus present?
Globally, the presenting features differ, which is one of the reasons 
that SLE can be difficult to diagnose. It remains problematic to 
establish whether a specific symptom or sign will occur in any 
individual or any group of patients, although cSLE is known to be 
more severe at diagnosis when compared with adult-onset SLE. 
In 2005, a cohort of 36 patients from Gauteng, including 14 black 
African children, was reported on, concluding that SLE is being 
increasingly recognised in black SA children.[11]
A recent study from Cape Town reports on 68 patients, with a median 
age of 12.2 years and an approximate female to male ratio of 5:1. The 
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study included a larger proportion of black 
and coloured patients than previous studies. 
This cohort of patients presented with severe 
disease at diagnosis, with most of them 
having LN. Preliminary findings show these 
children presenting with high disease activity 
and progression to end-organ damage at 
higher rates than in developed nations.[12]
Table 1 summarises the common clinical 
features of cSLE. Almost all children present with 
constitutional symptoms, e.g. fever, lymphadeno-
pathy and weight loss, mimicking tuberculosis 
(TB) and HIV in our setting.[13] Worldwide, 
common presenting features in cSLE are arthritis, 
malar rash and renal involvement.[4,13,14] 
In SA, cutaneous (77%) and constitutional 
(55.5%) features as well as renal involvement 
(44 - 50%) have been shown to be common 
presenting features. Other presenting features in 
SA children included serositis and Raynaud’s 
phenomenon.[11,12]
SLE presenting in childhood seems to 
have more frequent renal and neurological 
organ involvement, which heavily influences 
prognosis and therapy. It is essential to 




When investigating children with suspected 
SLE, the ACR criteria may be used to guide 
the initial investigations. Table 2 gives an 
out line of the investigations in a stepwise 
pattern.
Antinuclear antibody (ANA) testing 
and anti-extractable nuclear antigen form 
the mainstay of serological testing for SLE. 
Autoantibodies directed to nuclear antigens 
consist of various types of antibodies 
characterised by different antigen speci-
ficities. These nuclear antigens include 
single- and double-stranded DNA (ds DNA), 
histone proteins (histone DNA complex), 
nucleosome, centromere proteins and 
extractable nuclear antigens (including anti-
Smith, Ro, La, ribonucleoprotein). Under-
standing the specificities of the antibodies is 
useful in clinical practice to further classify 
patients with lupus and help predict their 
disease course.[15,16]
Management
The management of cSLE is difficult and 
referral to specialists in this field is essential. 
While there is no single cure for the disease, 
the aim of therapy at all stages of cSLE is 
to maximise the therapeutic effect while 
minimising disease activity and adverse 
effects. It is important to base treatment 
decisions on the systems/organs involved 
and the severity of the disease. SA is still 
trying to recover from the apartheid system 
and its inequalities in healthcare provision.[17] 
Recommendations can be made to offer our 
children the most appropriate management. 
The approach to management can be 
thought of as a 6-step process: using the 
multidisciplinary team (MDT), initial 
induction treatment, maintenance therapy, 
adjuvant therapy, managing disease flares, 
and disease monitoring.[8,18,19]
Multidisciplinary team 
All children with SLE should be managed 
in a specialist paediatric centre, preferably 
with access to paediatric rheumatologists, 
paediatric nephrologists and appropriate 
support staff. A comprehensive MDT is 
essential. Patients should be assessed 
individually and their specific needs 
addressed on a patient-to-patient basis. 
SLE is a life-long condition with a natural 
course of chronicity, with disease flares and 
accumulation of organ damage. Anticipating 
potential problems and planning for these in 
advance can help to reduce the impact of the 
disease on the patient and the child’s family. 
Adolescence is a dangerous time for all 
patients with chronic medical conditions, 
and lupus is no exception. There are many 
potential pitfalls at this time, including 
non-compliance, recreational drug use, 
psychosocial issues and pregnancy, which 
should be addressed. The transitional process 
through adolescence into adulthood should 
be carefully planned, with the involvement 
of the patient, their family and the MDT.
Initial induction treatment
Induction treatment should only be given 
after discussion with paediatric specialists, 
preferably those with knowledge of cSLE. 
This usually occurs in the first 6 - 12 months 
after diagnosis and is based on the use of 
high-dose immunosuppressive therapy 
to achieve disease stabilisation. Currently 
this is done initially with intravenous 
methylprednisolone (30 mg/kg per dose for 
3 days), together with immunosuppressive 
therapy and disease-modifying drugs. 
Weaning of the corticosteroid dose must 
be gradual and supervised carefully by an 
experienced team. 
Although the use of corticosteroids 
remains the first line of treatment, it is 
essential that every effort be made to 
minimise the dosage because of the 
extensive adverse effect profile. Steroid-free 
induction regimens are being developed and 
show some early promise as an appropriate 
treatment option, while reducing side-
effects.[8,18,19] 
Long-term efficacy has been demonstrated 
for intravenous cyclophosphamide-based 
regimens (500 - 750 mg/m2 per month for 
6 months). It can be particularly useful in 
patients with neurological, renal or systemic 
vasculitis and is more readily available 
in SA compared with some of the other 
immunosuppressive medications.[8,19] 
Mycophenolate mofetil (MMF) is an 
alternative treatment option and recent 
trials have demonstrated similar efficacy 
to cyclophosphamide, especially in patients 
with moderate to severe forms of LN, with a 
more favourable toxicity profile.[8,19] 
Azathioprine and methotrexate are other 
options available in SA. They are both used 
with corticosteroids in patients with mild to 
moderate disease. Azathioprine is useful in 
maintenance therapy for patients with LN 
and can be used to delay the presentation 
of neuropsychiatric manifestations of SLE. 
Methotrexate has been shown to be an 
effective agent in controlling cutaneous and 
articular manifestations of the condition.[19]
Newer biologics are currently being used 
for the treatment of cSLE, but are not readily 
available in SA.[20] Belimumab is the only 
biologic drug registered by the US Food and 
Drug Administration for use in SLE. It is a 
monoclonal antibody to the soluble human 
B lymphocyte stimulator protein and is the 
Table 1. Common clinical features of cSLE
Estimated presence of involvement, %
Clinical feature Paediatric SLE literature[4,13,14] South Africa [11,12]
Any constitutional feature 100 55.5
Fever 39
Lymphadenopathy 11 - 20 33.3
Arthritis 61 - 64 38.8
Nephritis 28 - 62 44.4
Mucocutaneous 77
Malar rash 55 - 62 47
Neuropsychiatric 15 - 20 19
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Table 2. Outline of investigations in stepwise pattern
Investigation Explanation
Initial essential investigations
Full blood count For anaemia, leucopenia and thrombocytopenia
Electrolytes, urea and creatinine Assess the renal function
Urine dipstick, microscopy, protein: creatinine 
ratio and urinary red blood cell casts
Check for both haematuria and proteinuria. LN is commonly present at diagnosis in children, 
especially in African children, and impacts on the initial management and long-term morbidity 
and mortality 
Complement levels – C3, C4 and total 
complement levels
Often reduced in SLE
ESR or CRP Indicates current inflammation
The level of ESR elevation may show a discrepancy relative to a normal CRP level in flares; 
if both markers are elevated, suspect the presence of an infective process 
Autoantibody and serological tests – immunological tests looking for autoantibodies should be performed
ANA These are the common autoantibodies found in patients with SLE – used as a screening test. 
By definition, all patients should be ANA positive at diagnosis. However, there are a small 
proportion of patients who are negative at diagnosis and become positive later in the disease. 
Not specific for SLE, as up to 30% of the population are low-titre positive 
Anti-ds DNA antibody High specificity but sensitivity only 70%. Level varies depending on disease activity, so can 
be used to monitor the clinical course. Shown to be increased in patients with LN and in 
neuropsychiatric lupus
Anti-Smith antibody Specific but not sensitive marker of SLE. Reactivity is not described in other diseases
Antiphospholipid antibodies: anticardiolipin, 
β2-glycoprotein-1 and lupus anticoagulant
Associated with the anti-phospholipid syndrome, cerebral vascular disease and 
neuropsychiatric lupus
Antinucleosome antibodies The first serological marker of SLE described and considered a major autoantigen in SLE – 
positive in about 85%. An excellent marker for SLE, playing an important role in pathogenesis. 
A good predictor of flares
Anti-Ro and anti-La antibody Particularly relevant in female adolescents who are considering having children. Known to play 
a role in the cardiac manifestations of neonatal lupus and photosensitivity
Syphilis test A false-positive serological test for syphilis is also in the ACR diagnostic criteria for SLE
Supplementary investigations, depending on history, examination and presenting clinical features
Liver function tests May be mildly elevated in acute SLE
Haemolysis work-up – includes a reticulocyte 
count, lactate dehydrogenase, haptoglobin, 
blood smear and a direct Coombs test
Perform if the haemoglobin level is low and/or haemolysis is suspected
Renal biopsy If renal involvement is present, a renal biopsy may be necessary. These should be classified 
according to the International Society of Nephrology and the Renal Pathology Society 
staging score
Chest radiograph For pericardial or pleural effusion, evidence of pericarditis, interstitial lung disease, pneumonitis and 
pulmonary embolism. In SA it is useful to look specifically for any radiological signs of tuberculosis
Electrocardiogram For evidence of pericarditis or pericardial effusion
Echocardiography For pericardial effusion or pulmonary hypertension
Tuberculin skin test Can be used mainly in younger patients to screen for tuberculosis
Ophthalmological examination For evidence of optic neuritis
Lumbar puncture To exclude infection with fever or neurological symptoms or signs. Nonspecific elevations in cell 
count and protein level and a decrease in glucose level may be found in the cerebrospinal fluid 
of patients with CNS lupus 
Brain magnetic resonance imaging/magnetic 
resonance angiography
To evaluate for CNS lupus white matter changes, vasculitis or stroke
Skin biopsy Can be helpful in diagnosing SLE in patients with unusual skin rashes. Many different rashes 
may indicate SLE and review by a dermatologist is important
CK May be elevated in myositis
ESR = erythrocyte sedimentation rate; CRP = C-reactive protein; ANA = antinuclear antibody; CNS = central nervous system; CK = creatinine kinase; LN = lupus nephritis.
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only biologic agent to demonstrate efficacy in adult SLE randomised 
controlled trials. Studies involving children are currently underway. 
Rituximab is currently being used off-label for select patients in 
the SA public health sector. It is commonly used for patients with 
SLE, despite the optimal dose of administration and indications of 
treatment being uncertain.[8,20]
Although not routine, plasma exchange and intravenous immuno globulin 
therapy are sometimes used by specialist physicians with experience of cSLE 
for specific indications. The main indications are in rapidly progressive 
life-threatening disease, neuropsychiatric lupus refractory to conventional 
treatment and idiopathic thrombocytopenic purpura.[19]
Maintenance therapy
Ongoing maintenance therapy is usually with weaning doses of 
oral corticosteroids in conjunction with disease-modifying agents 
as discussed above. Cyclophosphamide, MMF, azathioprine and 
rituximab are used, depending on disease severity and systems 
involved. Maintenance therapy has to be continued for several 
years to achieve ongoing disease remission and prevent steroid 
toxicity.[8,18,19]
Adjuvant therapy
An often overlooked key factor in the care of children with SLE is the 
importance of adjuvant therapy (Table 3).
Managing disease flares
Disease flares are a common occurrence in cSLE. They should be screened 
for and managed aggressively according to the severity of presentation and 
organ system involved. It is important to address compliance, changes in 
the social situation, as well as patient and family psychosocial well-being. 
Drug doses should be reviewed and may need to be altered according to 
the child’s growth. There is often a problem of accessing healthcare and 
medication in SA. These problems, although not always easy to solve, must 
be addressed in patients presenting with disease flares.[17] SLE patients are 
at an increased risk of infections – these should be actively sought for in 
any patient presenting with a disease flare. 
Disease monitoring
Deciding whether a child with SLE has a greater or lesser degree 
of disease activity and determining how to avoid disease damage 
are essential for patient management. It is not possible to use one 
individual clinical sign or laboratory value to measure the progression 
of the disease. To help with this, indices of disease activity and damage 
have been developed for use in adults with SLE; the same indices are 
being used in children.[14,22] 
Disease damage can be evaluated using the Systemic Lupus 
Erythematosus Disease Activity Index (SLEDAI) and the British Isles 
Lupus Assessment Group (BILAG) score.[23,24]
The only available instrument for measuring disease damage is 
the SLICC/ACR Damage Index, which looks at both disease-specific 
Table 3. Adjuvant therapy
Therapy Explanation
Antimalarials, e.g. hydroxychloroquine One of the most important recent advances in SLE management has been that all children with the 
condition must be treated with hydroxychloroquine. It plays a role in disease modification, helps with 
steroid sparing and can reduce the risk of disease flares. It is also associated with higher rates of 
renal response and fewer renal relapses[8,18,19]
NSAIDs NSAIDs have a role in reducing inflammation and giving symptomatic pain relief, especially for those 
with predominant musculoskeletal involvement. Care must be taken due to the adverse side-effect profile, 
particularly when dealing with children with LN, where these drugs may exacerbate renal disease[18]
Skin protection Skin protection from sunlight with specific clothing and high-factor sunscreen is critical, especially in a 
climate as in SA, and will reduce symptoms and long-term skin damage[18,19]
Vitamin and mineral supplementation, 
especially vitamin D
Essential to the general health of the patient. Vitamin D is most important in patients with 
photosensitivity, but should be given to all children with SLE, as it has recently been shown to have 
immunomodulatory effects[18,19]
Aspirin/anticoagulation Patients with SLE and positive antiphospholid antibodies but without a previous thrombotic event should 
receive low-dose aspirin. Patients with definite antiphospholipid syndrome and a previous thrombotic 
event require anticoagulation therapy, targeting an international normalised ratio of 2.0 - 3.0[19]
Angiotensin-converting enzyme 
inhibitors
Should be used to manage hypertension and proteinuria to reduce the risk of further organ damage[18]
Vaccinations Routine vaccination schedules should be used to keep children up to date with their immunisations, 
although caution is advised with regard to live vaccines in severely immunosuppressed children. Infections 
are the most common cause of death in patients with lupus, and pneumococcal infection is particularly 
prevalent. Therefore, pneumococcal and annual influenza vaccination should be encouraged[21]
Tuberculosis screening and prevention Tuberculosis is a highly prevalent condition in SA and a high index of suspicion is needed in lupus 
patients, especially if they are on immunosuppressive therapy. Regular screening may be necessary, 
depending on the disease prevalence and immune status of the patient. Isoniazid prophylaxis may be 
required in exposed at-risk patients
ESRD Renal dialysis and renal transplantation are options for patients with ESRD and transplantation has 
been shown to be effective in children with LN.[19] However, this results in a huge financial strain on an 
already over-burdened health system, and with the previous treatment, the aim is to halt the progression 
to ESRD in patients with LN
ESRD = end-stage renal disease; NSAIDs = non-steroidal anti-inflammatory drugs; 
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and non-disease-specific damage and quantifies non-reversible 
cumulative damage that has occurred since the onset of the disease.[22]
Mortality
In SLE, there is a bimodal pattern of mortality, either from initial 
disease activity or from complications relating to either the disease 
itself or therapies used in the treatment of the disease.[25] Renal 
disease is one of the major poor prognostic factors.[4] Recent 
improvements in early diagnosis, recognition of milder forms and 
improved management strategies account for the improvement in 
mortality in cSLE. In 1981, the 5-year survival rate for cSLE was 
reported as 82%, but in some more recent studies this figure has 
increased to 95%.[13]
According to Wadee et al.,[26] the 5-year survival probability was 
between 57% and 72% in SA adults. This was thought to be due to an 
inherently more aggressive disease pattern in black Africans. 
When to refer children with lupus
All SA children with SLE should be referred to a paediatric specialist. 
If the distance to travel is too far, a telephonic management plan 
should be made with a paediatric rheumatologist or nephrologist. A 
paediatric rheumatologist, nephrologist or paediatric specialist with 
an interest in lupus should see the child as soon as is feasible.
Summary
• Lupus in children is a rare but serious condition. Recent updates 
have shown that SLE is being increasingly recognised in southern 
Africa, particularly in black African children. In childhood SLE, 
there is a higher proportion of males affected than in adult-onset 
disease. 
• In SA, children present with severe disease, and renal involvement 
is common. 
• The management of cSLE needs to have early specialist input, and 
there should be access to a MDT.
Key points
• SLE is becoming increasingly recognised in black SA children.
• In SA, children present with severe disease, particularly with 
renal disease.
• Every patient with suspected lupus should have their urine 
analysed for protein and blood.
• A structured approach to investigation and management can help 
the overall care of the child.
• All children with SLE should be referred to a paediatric 
rheumatologist, nephrologist or paediatric specialist with know-
ledge of cSLE.
• A multidisciplinary approach to management is essential. 
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